{"id":"xibrom-and-optive","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging (Xibrom)"},{"rate":null,"effect":"Transient blurred vision (Xibrom)"},{"rate":null,"effect":"Mild ocular discomfort (Optive)"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Xibrom (bromfenac) works by blocking COX-1 and COX-2 enzymes, thereby reducing prostaglandin synthesis and decreasing ocular inflammation, pain, and photophobia. Optive is a preservative-free artificial tear formulation containing carboxymethylcellulose and glycerin that lubricates and protects the ocular surface, addressing dry eye symptoms through mechanical hydration rather than anti-inflammatory action.","oneSentence":"Xibrom is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye, while Optive is a lubricating eye drop that provides ocular surface hydration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:16:22.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative ocular inflammation and pain following cataract surgery (Xibrom)"},{"name":"Dry eye disease/ocular surface disease (Optive)"}]},"trialDetails":[{"nctId":"NCT00698724","phase":"PHASE4","title":"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Cataracts","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Xibrom, and Optive","genericName":"Xibrom, and Optive","companyName":"Bp Consulting, Inc","companyId":"bp-consulting-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xibrom is a small molecule used in the treatment of cataracts, as indicated by ClinicalTrials.gov. Optive is also used in the treatment of cataracts, as shown by ClinicalTrials.gov, although its mechanism is not specified.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}